Medtronic: Guidance Built To Be Beaten - Buy

Medtronic plc is rated buy with a $92 price target, reflecting conservative fiscal 2027 guidance and resilient growth platforms. Fiscal 2026 delivered $36.4B in revenue, the strongest growth in a decade, led by Cardiovascular and ablation solutions outpacing market rates.

Guidance for fiscal 2027 excludes potential catalysts—MiniMed separation, tariff refunds, and Blackstone payment relief—implying room for upside surprises. Organic growth above 5% is critical; litigation, tariffs, and MiniMed execution remain key risks, but current valuation provides limited downside.